Pyridines in Drug Discovery
Pyridine has a strong claim to being the single most useful nitrogen heterocycle in medicinal chemistry. Swapping one CH for N gives a ring with the planarity and aromaticity of benzene but with an sp²-hybridised nitrogen with a lone pair available that reshapes lipophilicity, solubility, and hydrogen bonding all at once. That combination is why pyridine turns up so often when a team is trying to fix a compound's metabolic stability or improve its lipophilicity profile without losing potency. Beyond simple phenyl replacement, pyridine frequently serves as a handle for tuning pKa, reducing lipophilicity and introducing directional hydrogen-bonding interactions without dramatically changing molecular size. A recent structural survey of FDA-approved small molecules bearing this ring found 54 pyridine-containing drugs approved between 2014 and 2023 alone, spanning at least eight distinct therapeutic categories, from anticancer agents and CNS drugs to antibiotics, antivirals, antifungals, hematopoietic agents, rare disease treatments, and diagnostic contrast agents. Kinases dominate the target list, and cancer accounts for roughly a third of the approvals in that window. Tovorafenib is a good illustration of what the ring is doing mechanistically rather than just decoratively. Approved in 2024 as the first systemic therapy for pediatric low-grade glioma with a BRAF alteration, its trifluoromethyl-substituted pyridine ring sits directly in the hydrophobic pocket vacated by the DFG motif phenylalanine when the kinase flips to its inactive conformation. The pyridine ring is not simply a hydrophobic substituent. It contributes directly to the type II binding mode by occupying this pocket, while its substitution pattern helps optimise interactions. None of this is new territory for medicinal chemists, but the breadth of therapeutic areas where the ring keeps proving useful is a reminder of how much design flexibility a single heterocycle can offer. Explore our range of building blocks using the advanced search tools at https://lnkd.in/eVbfw6Ua To read more, take a look at the following interesting papers: 1. A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis https://lnkd.in/e\_mzcM8n 2. Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure-activity relationships, and ADMET liabilities https://lnkd.in/gHCKvuH6 3. The Structure-Antiproliferative Activity Relationship of Pyridine Derivatives https://lnkd.in/eaqBKnBA
![Azabicyclo[3.1.0]hexane](https://shop.activate-scientific.com/media/ab/77/94/1778843911/layers.svg?ts=1778843911){kind=icon}
![Bicyclo[1.1.1]pentane](https://shop.activate-scientific.com/media/88/e1/3b/1778844138/share-2.svg?ts=1778844138){kind=icon}
.svg?ts=1778844369){kind=icon}
